https://www.ft.com/content/5730d761-2a7e-470f-8bee-953b64f7775d
Hepatology Communications Publishes Data From Mirum’s LIVMARLI In Primary Sclerosing Cholangitis
First and only data evaluating IBAT inhibition in treating primary sclerosing cholangitis (PSC)
Data provided proof-of-concept for Phase 2b VISTAS study evaluating volixibat, an IBAT inhibitor, in patients with